The present invention provides matched antibody pairs for the specific detection of one or more of the four dengue virus serotypes in a biological sample that may contain one or more of such dengue virus serotypes. Each matched antibody pair is capable of detecting not more than one serotype of dengue virus NS1 protein that may be present in the sample and will not cross react with other serotypes that may be present in the sample. Multiple matched pairs may be used to detect one or more dengue virus serotypes that may be present in a sample. Such matched pair antibodies, facilitate the development of confirmatory in vitro diagnostic tests such as sandwich immunoassays, that detect and distinguish the presence of one or more dengue virus serotypes in a biological sample, preferably a sample derived from human subject. The invention also provides kits comprising the matched antibody pairs of the invention and methods for using the kits for immunoassays for the specific detection of one or more serotypes of dengue virus in a patient population. The present invention also provides monoclonal antibodies specific for the NS1 protein of dengue virus and therapeutic compositions and methods for treating dengue virus infection.

The present invention provides a lateral flow multiplex assay strip, and lateral flow assay systems and kits comprising the assay strips of the invention and methods of using the assay strip and systems and kits to detect the levels of two or more target analytes that may be present in a liquid sample, wherein the two more target analytes are detectable at a single test area of the assay.

Disclosed herein are methods and devices for pathogen or antibody detection using unmodified signaling substances with or without unlabeled detection reagents. Unmodified signaling substance include, but are not limited to, a molecule, a material or a part of a material that is not modified with an antibody, an antigen, a pathogen, a DNA probe or an aptamer molecule. Unlabeled detection reagent refers to an antibody, an antigen, a pathogen, a DNA probe, or an aptamer that is not labeled with a signaling molecule such as enzyme, biotin, streptavidin, fluorescence or chemiluminescence probe, etc.

The present disclosure provides for engineered microorganisms and methods of making and using same. The engineered microorganisms as described herein can have a surface display and can be useful as therapeutic agents (e.g., sponges) and biosensors.

Disclosed herein are immunoassay methods and reagents for detecting anti-Zika IgM antibody in a biological sample from a subject and/or diagnosing Zika virus infection in a subject. Also disclosed are algorithms for implementing the disclosed methods. The disclosed immunoassay methods, reagents, and algorithms enable efficient and reliable qualitative detection of anti-Zika virus antibodies and rapid determination of presumptive positive results for Zika virus infection in human subjects.

Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.

Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication. Uses of a Molecular Net may include analyte capture, analyte enrichment, analyte purification, analyte detection, analyte measurement and analyte delivery. Molecular Nets may be used in liquid phase or on solid phases such as nanomaterials, modified metal surfaces, nanospheres, microspheres, microtiter plates, slides, pipettes, cassettes, cartridges, discs, probes, lateral flow devices, microfluidics devices, microfluidics devices, optical fibers and others.

Disclosed herein are compositions, kits and methods for determining the concentration of fluid-phase MASP-2/C1-INH complex in a biological fluid, such as a biological fluid obtained from a subject infected with SARS-CoV-2. Also disclosed are methods of using said compositions, methods and kits for detection of MASP-2/C1-INH complex to determine the status of lectin pathway activation in a mammalian subject and thereby assess the risk of a subject that is or has been infected with SARS-CoV-2 for developing COVID-19-related ARDS or other poor outcome, or determine the need for treatment or efficacy of treatment of a subject in need thereof with a complement inhibitor such as a MASP-2 inhibitory agent.

The present invention relates to nucleic acids. In particular, it relates to aptamers capable of binding to a flavivirus structural protein or a flavivirus non-structural protein, useful as therapeutics for preventing, treating and/or diagnosing a flavivirus infection in a patient.

Disclosed is a method for measuring a viral antigen using a capture antibody and a detection antibody, the method comprising forming a sandwich immune complex that contains the capture antibody, the viral antigen and the detection antibody, the capture antibody comprising a heavy chain variable region that comprises CDR1 comprising amino acid sequence of SEQ ID NO: 1, CDR2 comprising amino acid sequence of SEQ ID NO: 2 and CDR3 comprising amino acid sequence of SEQ ID NO: 3, and a light chain variable region that comprises CDR1 comprising amino acid sequence of SEQ ID NO: 4, CDR2 comprising amino acid sequence of SEQ ID NO: 5 and CDR3 comprising amino acid sequence of SEQ ID NO: 6, and the detection antibody comprising a heavy chain variable region that comprises CDR1 comprising amino acid sequence of SEQ ID NO: 7, CDR2 comprising amino acid sequence of SEQ ID NO: 8 and CDR3 comprising amino acid sequence of SEQ ID NO: 9, and a light chain variable region that comprises CDR1 comprising amino acid sequence of SEQ ID NO: 10, CDR2 comprising amino acid sequence of SEQ ID NO: 11 and CDR3 comprising amino acid sequence of SEQ ID NO: 12.